Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

PharmaCielo Ltd. (V:PCLO)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 82 Richmond Street East
TORONTO ON M5C 1P1
Tel: N/A
Website: https://www.pharmacielo.com
IR: See website
Key People
Marc Lustig
Chairman of the Board, Chief Executive Officer
Ian D. Atacan
Chief Financial Officer, Director
Andres Botero
Chief Operating Officer
Business Overview
PharmaCielo Ltd. is a Canada-based company with a focus on ethical and sustainable processing and supplying of all natural, pharmaceutical-grade medical cannabis products to channel distributors. The Company has two subsidiaries, PharmaCielo Colombia Holdings S.A.S. (PharmaCielo Colombia) and Ubiquo Telemedicina S.A.S. (Ubiquo). PharmaCielo Colombia cultivates and processes the Company's all-natural cannabis into standardized, medicinal-grade oil extracts and related products. In Colombia, PharmaCielo Colombia is a licensed cultivator, producer, and distributor of both TetraHydroCannabinol (THC) and Cannabidiol (CBD) medical cannabis for use in Colombia, international export, and research purposes. Ubiquo is a knowledge management and medical consultation system that focuses on creating access to healthcare for Colombians. Ubiquo is a technology platform and a user interface that allows doctors and patients to communicate. Ubiquo is used as a communication tool.
Financial Overview
For the nine months ended 30 September 2023, Pharmacielo Ltd revenues decreased 66% to C$1.3M. Net loss applicable to common stockholders decreased 15% to C$9.9M. Revenues reflect Sale of Cannabis derivative products decrease of 68% to C$1.2M. Lower net loss reflects Salaries and wages decrease of 25% to C$3.1M (expense), Amortization and depreciation decrease of 78% to C$280K (expense).
Employees: 268 as of Dec 31, 2019
Reporting Currency: Canadian Dollars
Enterprise value: $46.93M as of Sep 30, 2023
Annual revenue (TTM): $2.81M as of Sep 30, 2023
EBITDA (TTM): -$8.69M as of Sep 30, 2023
Net annual income (TTM): -$12.82M as of Sep 30, 2023
Free cash flow (TTM): -$5.19M as of Sep 30, 2023
Net Debt Last Fiscal Year: $16.77M as of Sep 30, 2023
Shares outstanding: 169,745,157 as of Mar 26, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization